title: Development of Myasthenia Gravis in a Patient with Chronic Myeloid Leukemia during Treatment with Nilotinib.
abstract: We report on a patient diagnosed with chronic myeloid leukemia (CML) who developed myasthenia gravis while on treatment with nilotinib. Autoimmune disease, including the development of myasthenia gravis, has been described in association with CML as well as the use of tyrosine kinase inhibitors. Second generation tyrosine kinase inhibitors are highly effective in the treatment of CML, although can result in adverse effects related to off-target kinase inhibition, and longer term reporting of adverse effects is required.
authors.affiliation: Department of Medicine, Division of Hematology, University of Western Ontario , London, ON, Canada.
authors.forename: David
authors.initials: D
authors.lastname: Sanford
authors.affiliation: Department of Oncology, University of Western Ontario , London, ON, Canada.
authors.forename: Maria
authors.initials: M
authors.lastname: MacDonald
authors.affiliation: Department of Oncology, University of Western Ontario , London, ON, Canada ; Department of Clinical Neurological Sciences, University of Western Ontario , London, ON, Canada.
authors.forename: Michael
authors.initials: M
authors.lastname: Nicolle
authors.affiliation: Department of Medicine, Division of Hematology, University of Western Ontario , London, ON, Canada.
authors.forename: Anargyros
authors.initials: A
authors.lastname: Xenocostas
keywords: adverse drug events; chronic myeloid leukemia; tyrosine kinase inhibitors